98 related articles for article (PubMed ID: 24724578)
1. Stability of HE4 and CA125 in blood samples from patients diagnosed with ovarian cancer.
Sandhu N; Karlsen MA; Høgdall C; Laursen IA; Christensen IJ; Høgdall EV
Scand J Clin Lab Invest; 2014 Sep; 74(6):477-84. PubMed ID: 24724578
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?
Azzam AZ; Hashad DI; Kamel NA
Arch Gynecol Obstet; 2013 Jul; 288(1):167-72. PubMed ID: 23361457
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
[TBL] [Abstract][Full Text] [Related]
4. CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management.
Presl J; Novotny Z; Topolcan O; Vlasak P; Kucera R; Fuchsova R; Vrzalova J; Betincova L; Svobodova S
Anticancer Res; 2014 Jan; 34(1):327-31. PubMed ID: 24403483
[TBL] [Abstract][Full Text] [Related]
5. Combined detection of sialic acid and hydroxyproline in diagnosis of ovarian cancer and its comparison with human epididymis protein 4 and carbohydrate antigen 125.
Li PL; Zhang X; Li TF; Wang LL; Du LT; Yang YM; Li J; Wang HY; Zhang Y; Wang CX
Clin Chim Acta; 2015 Jan; 439():148-53. PubMed ID: 25445414
[TBL] [Abstract][Full Text] [Related]
6. The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay.
Yang J; Sa M; Huang M; Yang J; Xiang Z; Liu B; Tang A
Clin Biochem; 2013 Nov; 46(16-17):1705-8. PubMed ID: 24012857
[TBL] [Abstract][Full Text] [Related]
7. HE4 is an independent prognostic marker in endometrial cancer patients.
Mutz-Dehbalaie I; Egle D; Fessler S; Hubalek M; Fiegl H; Marth C; Widschwendter A
Gynecol Oncol; 2012 Aug; 126(2):186-91. PubMed ID: 22525819
[TBL] [Abstract][Full Text] [Related]
8. The Establishment of an HE4-CLIA Method and the Combined Analysis of HE4 and CA125 in Ovarian Cancer.
Zhang Q; Wang CR; Yu JP; Ma Q; Xu WW
J Clin Lab Anal; 2016 Sep; 30(5):709-18. PubMed ID: 26990679
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases.
Park Y; Lee JH; Hong DJ; Lee EY; Kim HS
Clin Biochem; 2011 Jul; 44(10-11):884-8. PubMed ID: 21549107
[TBL] [Abstract][Full Text] [Related]
10. [Ovarian tumor markers of presumed benign ovarian tumors].
Lahlou N; Brun JL
J Gynecol Obstet Biol Reprod (Paris); 2013 Dec; 42(8):752-9. PubMed ID: 24210243
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of HE4 change little during in vitro fertilization.
Hallamaa M; Huhtinen K; Suvitie P; Perheentupa A
Acta Obstet Gynecol Scand; 2014 Jul; 93(7):640-6. PubMed ID: 24734893
[TBL] [Abstract][Full Text] [Related]
12. HE4 and ROMA index in Czech postmenopausal women.
Novotny Z; Presl J; Kucera R; Topolcan O; Vrzalova J; Fuchsova R; Betincova L; Rokyta Z
Anticancer Res; 2012 Sep; 32(9):4137-40. PubMed ID: 22993374
[TBL] [Abstract][Full Text] [Related]
13. The clinical significance of the combined detection of serum Smac, HE4 and CA125 in endometriosis-associated ovarian cancer.
Xu XR; Wang X; Zhang H; Liu MY; Chen Q
Cancer Biomark; 2018 Feb; 21(2):471-477. PubMed ID: 29226858
[TBL] [Abstract][Full Text] [Related]
14. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
[TBL] [Abstract][Full Text] [Related]
15. Serum human epididymis protein 4 vs. carbohydrate antigen 125 in ovarian cancer follow-up.
Ferraro S; Robbiano C; Tosca N; Panzeri A; Paganoni AM; Panteghini M
Clin Biochem; 2018 Sep; 60():84-90. PubMed ID: 30125544
[TBL] [Abstract][Full Text] [Related]
16. [HE4--a new tumor marker for ovarian cancer].
Manolov V; Marinov B; Vasilev V; Andreeva A
Akush Ginekol (Sofiia); 2011; 50 Suppl 2():11-5. PubMed ID: 22524132
[TBL] [Abstract][Full Text] [Related]
17. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC
Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248
[TBL] [Abstract][Full Text] [Related]
18. HE4 as an Early Detection Biomarker of Epithelial Ovarian Cancer: Investigations in Prediagnostic Specimens From the Janus Serumbank.
Gislefoss RE; Langseth H; Bolstad N; Nustad K; Mørkrid L
Int J Gynecol Cancer; 2015 Nov; 25(9):1608-15. PubMed ID: 26501436
[TBL] [Abstract][Full Text] [Related]
19. [Serum tumor markers CA125 and HE4 in ovarian cancer patients].
Sergeeva NS; Marshutina NV; Alentov II; Korneeva IA; Novikova EG
Vopr Onkol; 2013; 59(2):12-21. PubMed ID: 23814844
[No Abstract] [Full Text] [Related]
20. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET).
Antonsen SL; Høgdall E; Christensen IJ; Lydolph M; Tabor A; Loft Jakobsen A; Fagö-Olsen CL; Andersen ES; Jochumsen K; Høgdall C
Acta Obstet Gynecol Scand; 2013 Nov; 92(11):1313-22. PubMed ID: 24032654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]